Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Mediterranean diet cut Parkinson’s risk
MDedge Cardiology
A prescription for medicine’s gender inequality
MDedge Cardiology
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Cardiology
Trump targets abortion by denying family planning funds
MDedge Cardiology
Online vitriol’s expansion into doctor discussion sites
MDedge Cardiology
Caring for aging HIV-infected patients requires close attention to unrelated diseases
MDedge Cardiology
Commentary: Should AVFs be ligated after kidney transplant?
MDedge Cardiology
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Cardiology
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Cardiology
Infective endocarditis isn’t what it used to be
MDedge Cardiology